Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology
Shots:
- Takeda has entered into strategic collaboration & licensing agreement with BridGene bioscience to identify novel small molecules in immunology & neurology
- As per the terms, Takeda will gain exclusive rights to develop & commercialize products arising from the deal in exchange for an upfront & preclinical milestone totalling to $46M, plus ~$770M in clinical & commercial milestones as well as net sales-based tiered royalties
- Collaboration will leverage BridGene’s Imtac platform & its chemoproteomics-based approach to screen small molecules across all proteins in live cells to tackle traditionally undruggable or 'hard-to-drug' targets
Ref: Prnewswire | Image: BridGene & Takeda
Related News:- Neurocrine Biosciences and Takeda Amend Partnership to Develop and Commercialize Osavampator in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
